California Oncology Research Institute
2336 Santa Monica Boulevard #206
Santa Monica, California 90404
Tel: (310) 696-0716
Fax: (310) 696-0724
Email: abilchik@aol.com or abilchik@mednet.ucla.edu

Medical Director, California Oncology Research Institute

Professor, David Geffen School of Medicine at UCLA

Golden Apple Award “Outstanding Teacher”
UCLA General Surgery

Vice Chair of Surgery, St. John’s Hospital

America’s Top Doctor – Surgery

America’s Top Doctor – Surgery

America’s Top Doctor – Surgery

America’s Top Doctor – Surgery

Chief of Surgery, Century City Hospital

Member, Society Surgical Oncology

Member, Pacific Coast Surgical Society

Local Program Chairman, Society of Surgical Oncology

Program committee, American Hepatobiliary Association

Western Surgical Association

Society of Surgical Oncology

Ad hoc Reviewer, Cancer

Editorial Board, Annals of Surgical Oncology

Ad hoc Reviewer, Journal of American College of Surgeons

Ad hoc Reviewer, World Journal of Surgery

Study Section “H” Review of Cancer Cooperative Groups and Grants

Surgical Oncology

Ultrastaging of Gastrointestinal Malignancies

Radioimmunoassay of peptides in pathophysiological conditions.

Role of cholecystokinin in the control of growth and regulation of the pancreas.

Pathophysiology of an endocrine tumor-peptic ulcer model.

Molecular and physiological regulation of small bowel absorption.

Molecular profiling of gastrointestinal malignancies.

Immunotherapy of gastrointestinal malignancies.

Amelioration of traumatic pancreatitis by CCK antagonist.
OHSE research award-Yale University. $10,000, PI – AJ Bilchik M.D.

Bacterial and specific contribution to the mortality of post traumatic pancreatitis
in a guinea pig model.
OHSE research award-Yale University. $9,500, PI – AJ Bilchik M.D

Oncogene expression in mastomys carcinoid tumors.  OHSE research fund award-Yale University. $10,000, PI – AJ Bilchik M.D

Surgery and intestinal absorption.
NIH DK39870-05. (Co-investigator) $600,000, PI – MJ Zinner

Early diagnosis and treatment of pancreatic cancer.
SPORE institutional grant (Collaborator)

Molecular Detection of Colon Cancer with a Multiple Marker PCR Assay.
  Rod Fasone Fund $10,000

Rogavin-Davidow Foundation $75,000

Polyvalent Vaccine: Phase III Trial in Stage IV Melanoma
NIH/NCI 5 P-01 CA29605-18  $878,746, PI – DL Morton M.D.

New Approaches to Surgical Oncology
NIH/NCI 5 P01 CA 29605-18 $2,218,374, PI – DL Morton M.D.

Rod Fasone Fund $15,000

Rogavin-Davidow Foundation $75,000

Surgery, Immunology and Immunology of Human Cancer
NIH/NCI 5 P01 CA12582-28  $3,810,835, PI – DL Morton, M.D.

Unrestricted research grant - Rita Medical Incorporated  $50,000

Rod Fasone Fund $10,000

Ultrastaging of Early Colon Cancer Using Lymphatic Mapping and Sentinel Node Analysis $150,000, PI - AJ Bilchik M.D. Ph.D.

1.  Ultrastaging of Early Colon Cancer Using Lymphatic Mapping and Sentinel Node Analysis NIH/NCI 1 R01 CA90848-01  $2,631,076, PI – AJ Bilchik M.D. Ph.D.

Carbohydrate Antigens As Targets for Vaccine Immunotherapy in Colon Cancer NIH/NCI K08 Grant (submitted), PI – AJ Bilchik M.D. Ph.D.

Carbohydrate Antigens As Targets for Vaccine Immunotherapy in Colon Cancer American Cancer Society Beginning Investigators Grant (submitted), PI - AJ Bilchik M.D. Ph.D.

Rogavin-Davidow Foundation $75,000

Polyvalent Vaccine: Phase III Trial in Stage IV Colon Cancer, PI – AJ Bilchik, M.D., Ph.D.

Rod Fasone Fund $15,000

George Hoag Foundation $35,000

Rogavin-Davidow Foundation $75,000

SPORE in Pancreas Cancer, Co-Investigator – AJ Bilchik M.D. Ph.D., PI – T Adrian, Ph.D.

William Randolph Hearst Foundation $500,000

Davidow Charitable Fund $75,000

Davidow Charitable Fund $75,000

Davidow Charitable Fund $75,000

Davidow Charitable Fund $75,000

William Randolph Hearst Foundation $150,000

Ultrastaging of Early Colon Cancer. NIH/NCI 2RO1 CA90848-05A2 $2,638,184

1. Vellet D, Leiman G, Mair S, Bilchik AJ.  Fine needle aspiration cytology of mucinous cystadenocarcinoma of the pancreas: Further observations.  Acta Cytol 1988;32:43-48.
2. Longo WE, Ballantyne GH, Vukasin AP, Bilchik AJ, Adrian TE, Modlin IM. Deoxycholic acid release of peptide YY from colonic endocrine cells: a specific and non neurally mediated mechanism.  Surg Forum 1988;39:182-183.
3. Basson MD, Fielding LP, Bilchik AJ, Zucker KA, Ballantyne GH, Adrian TE, Modlin IM. Does VIP mediate the pathophysiology of bowel obstruction? Am J Surg 1989;157:109-115.
4. Longo WE, Ballantyne GH, Bilchik AJ, Modlin IM. Advanced rectal cancer: What Is the Best Palliation? Dis Colon Rectum 1989;31(11):842-847.
5. Zucker KA, Longo WE, Bilchik AJ, Adrian TE, Modlin IM. Malignant diathesis from jejunal-ileal carcinoids. Am J Gastroenterol 1989;84(2):182-186.
6. Modlin IM, Bilchik AJ, Zucker KA, Adrian TE, Graham S, Sussman J. Cholecystokinin augmentation of surgical pancreatitis: Benefits of receptor blockade. Arch Surg 1989;124:574-578.
7. Bilchik AJ, Modlin IM, Nilsson O, Zucker KA, Adrian TE. H2 receptor blockade induces peptide YY (PYY) and enteroglucagon (EG) secreting gastric carcinoids in mastomys. Surgery 1989;106(6):1119-1127.
8. Zucker KA, Bilchik AJ, Adrian TE, Modlin IM. Postaglation E analogue inhibition of pancreatic enzyme secretion. Pancreas 1989;4(6):708-714.
9. Ballantyne GH, Longo WE, Adrian TE, Vukasin A, Bilchik AJ, Modlin IM. Deoxycholate stimulated release of peptide YY from isolated perfused rabbit colon: a specific and non-neurally mediated mechanism. Am J Physiol 1989;257:G715-G724.
10. Zucker KA, Adrian TE, Bilchik AJ, Modlin IM. Effects of the CCK receptor antagonist L364,718 on pancreatic growth in adult and developing animals. Am J Physiol 1989;257:G511-516.
11. Savoca PE, Ballantyne GH, Adrian TE, Bilchik AJ, Modlin IM. cAMP mediated release of PYY from the isolated perfused colon: Evidence for negative feedback modulation of colonic secretion. Surg Forum 1989;40:177-180.
12. Adrian TE, Zucker KA, Bilchik AJ, Modlin IM. A novel micro-method for pancreatic acinar secretion: Time course of CCK stimulation and its inhibition by L364,718. Int J Pancreatol 1990;6(1):61-69.
13. Bilchik AJ, Zucker KA, Adrian TE, Sussman J, Modlin IM. Cholecystokinin receptor blockade ameliorates pancreatitis in a new surgical model. Surg Res Commun 1990;8(1):47-57.
14. Bilchik AJ, Nilsson O, Modlin IM, Zucker KA, Adrian TE. Significance of gastric endocrine tumor and age related gut peptide alterations in mastomys. Regul Peptides 1990;27(2):195-207.
15. . Nillson O, Bilchik AJ, Adrian TE, Modlin IM. Intraocular transplantation of carcinoid tumors from mastomys and humans. J Pathol 1990;160(4):347-356.
c
16. Bilchik AJ, Zucker KA, Adrian TE, Modlin IM. Amelioration of cholinergic-induced pancreatitis with a selective cholecystokinin receptor antagonist. Arch Surg 1990;125(12):1546-1549.
17. Bilchik AJ, Ballantyne GH, Modlin IM. Removal of malignant polyps is best done conservatively: A surgeon’s perspective. Debates Med 1990; Volume 3.
18. Modlin IM, Bilchik AJ, Goldenring JR. Enterochromaffin-like cell tumor induction in mastomys by insurmountable H2 receptor blockade. Res Clin Forums 1990;12:59-80.
19. Bilchik AJ, Leach SD, Zucker KA, Adrian TE, Modlin IM. Experimental models of acute pancreatitis. J Surg Res 1990;48(6):639-647.
20. Longo We, Ballantyne GH, Adrian TE, Bilchik AJ, Modlin IM. Short chain fatty acid release of PYY in the isolated rabbit distal colon. Scand J Gastroenterol 1991;26:4424-4448.
21. . Armstrong D, Ballantyne GH, Bilchik AJ, McMillen A, Adrian TE and Modlin IM. Adaptive increase in peptide YY and enteroglucagon after proctocolectomy and pelvic ileal reservoir construction. Dis Colon Rectum 1991;34(2):119-25.
22. Nilsson O, Bilchik AJ, Goldenring JR, Ballantyne GH, Adrian TE, Modlin IM. Distribution and immunocytochemical colocalization of peptide YY and enteroglucagon in endocrine cells of the rabbit colon. Endocrinology 1991;129(1):139-148.
23. Modlin IM, Kim H, Bilchik AJ, Nilsson O, Esterline WJ, Goldenring JR. Pathobiology of enterochromaffin-like tumor induction in mastomys. The stomach as an endocrine organ. Eds. Hakanson R and Sundler F. Elsevier 1991;33:499-513.
24. Vukasin AP, Ballantyne GH, Nilsson O, Bilchik AJ, Adrian TE, Modlin IM. Plasma and tissue alterations of peptide YY and enteroglucagon in rats after colectomy. Yale J Biol Med 1992;65(1):1-15.
25. Leach SD, Bilchik AJ, Karapetian O, Gorelick FS, Modlin IM. Influence of choloroquine on diet-induced pancreatitis. Pancreas 1993;8(1):64-69.
26. Bilchik AJ, Hines OJ, Adrian TE, Skotzko MJ, McFadden DW, Zinner MJ, Ashley SW. PYY gene expression is an early adaptive response to massive small bowel resection. Surg Forum 1993;44:126-128.
27. Adrian TE, Ballantyne GH, Longo WE, Bilchik, AJ, Graham S, Basson MD, Tierney RP and Modlin IM. Deoxcholate is an important releaser of peptide YY and enteroglucagon from human colon. Gut 1993;34:198-206.
28. Hines OJ, Bilchik AJ, Skotzko MJ, Zinner MJ, McFadden DW, Ashley SW. Translational control of meal-induced absorption. Surg Forum 1993;44:133-134.
29. Herrington MK, Permert J, Kazakoff KR, Pour PM, Zucker KA, Bilchik AJ, Adiran TE. Effects of high fat diet and cholecystokinin receptor blockade on pancreatic growth and tumor initiation in the hamster. Carinogenesis 1993;14(5):1021-1026.
30. Ballantyne GH, Goldenring JR, Bilchik AJ, Adrian TE, Modlin IM. cAMP-mediated release of peptide YY from the isolated perfused rabbit distal colon. Regul Peptides 1993;47:117-126.
31. Bilchik AJ, Hines OJ, Adrian TE, McFadden DW, Berger JJ, Zinner MJ, Ashley SW. Peptide YY is the physiological regulator of water and electrolyte absorption in the canine small bowel in vivo. Gastroenterology 1993;105:1441-1448.
32. Modlin IM, Lewis JJ, Bilchik AJ, Kumar RR. Management of unresectable malignant endocrine tumors of the pancreas. Surg Gynecol Obstet 1993;176(5):507-518.
33. Bilchik AJ, Hines OJ, Zinner MJ, Adrian TE, Bereger JJ, Ashley SW, McFadden DW. Peptide YY augments postprandial small intestinal absorption in vivo. Am J Surgery 1994;167(6):570-574.
34. . Hines OJ, Bilchik AJ, Zinner MJ, Skotzko MJ, McFadden DW, Ashley SW. Adaptation of the Na+/glucose cotransporter following intestinal resection. J Surg Res 1994;57(1):22-27.
35. Herrington MK, Permert J, Kazakoff KR, Zucker KA, Bilchik AJ, Pour PM, Adrian TE. Effects of raw soya diet and cholecystokinin receptor blockade on pancreatic growth and tumor initiation in the hamster. Cancer Letters 1994;82:7-16.
36. Hines OJ, Bilchik AJ, McFadden DW, Zinner MJ, Ashley SW. Upregulation of the Na+/K+ ATPase following massive intestinal resection. Surgery 1994;116(2):401-408.
37. Bilchik AJ, Hines OJ, Adrian TE, Ashley SW, Zinner MJ, McFadden DW. Peptide YY immunoneutralization inhibits meal induced absorption in vivo. Surgery 1994;116:1153-1158.
38. Hines OJ, Bilchik AJ, Ashley SW, Zinner MJ, McFadden DW. Amino acids mediate postprandial jejunal postprandial absorption. J Surg Res 1995;58:81-85.
39. Bilchik AJ, Hines OJ, Adrian TE, Zinner MJ, McFadden DW, Ashley SW. Early regional expression and secretion of peptide YY and enteroglucagon after massive small bowel resection. J Am Coll of Surg 1995;180:417-426
40. Hines OJ, Bilchik AJ, Rodgers PJ, Berger J, Zinner MJ, Ashley SW. Na+/H+ exchange regulates postprandial ileal water and electrolyte absorption. Dig Dis Sci 1995;40:774-780.
41. Liu CD, Aloia T, Adrian TE, Bilchik AJ, Ashley SW, Zinner MJ, McFadden DW. Peptide YY; a potential proabsorptive hormone for the treatment of malabsorptive disorders. Am Surg 1996;62(3):232-236.
42. Whang EE, Hines OJ, Bilchik AJ, Zinner MJ, McFadden DW, Ashley SW. Antisecretory mechanisms of peptide YY in rat distal colon. Dig Dis Sci 1997;42(6):1121-1127.
43. Bilchik AJ, Sarantou T, Wardlow J, Ramming K. Cryosurgery causes a profound reduction in tumor markers in hepatoma and non-colorectal hepatic metastases. Am Surg 1997;63: 796-800.
44. Bilchik AJ, Sarantou T, Foshag LJ, Giuliano A, Ramming KP. Cryosurgical palliation of metastatic neuroendocrine tumors resistant to conventional therapy. Surgery 1997;122:1040-1048.
45. Sarantou T, Bilchik AJ, Ramming KP. Complications of hepatic cryosurgery. Semin Surg Oncol 1998;14:156-162.
46. Bilchik AJ. Editorial Cryotherapy of liver tumors. Oncology July 1998.
47. Bilchik AJ, Giuliano AE, Essner R, Bostick PJ, Kelemen P, Foshag LJ, Sostrin S, Turner RR, Morton DL. Universal application of intraoperative lymphatic mapping and sentinel lymphadenectomy in solid neoplasms. Cancer J Sci Am 1998;4(6):351-358.
48. Chu KU, Turner RR, Hansen NM, Brennan MB, Bilchik AJ, Giuliano AE. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg 1999;229:536-541.
49. Rose DM, Allegra DP, Bostick PJ, Foshag LJ, Bilchik AJ. Radiofrequency ablation: a novel primary and adjunctive ablative technique for hepatic malignancies. Am Surg 1999;65:1009-1014.
50. Bilchik AJ, Rose DM, Bostick PJ, Chu K, Allegra D, Morton DL. Radiofrequency ablation – a minimally invasive technique with multiple applications. Cancer J Sci Am 1999;5(6):356-361.
51. Bilchik AJ, Rose DM, Hsueh E, Foshag LJ, Morton DL. Cryosurgery and radiofrequency ablation of unresectable hepatic malignancies: A proposed algorithm. Arch Surg 2000;135(6):657-664.
52. Hines OJ, Whang EE, Bilchik AJ, Zinner MJ, Welton M, Lane J, McFadden DE, Ashley SW. Role of Na+/-glucose co-transport in jejunal meal-induced absorption. Dig Dis Sci 2000;45:1-6.
53. Bilchik AJ, Miyashiro M, Kelley M, Kuo C, Fujiwara Y, Nakamori S, Monden M, Hoon DSB. Molecular detection of metastatic pancreatic carcinoma cells using a multimarker RT-PCR assay. Cancer 2000;88:1037-1044.
54. Chu KU, Ravindranath MH, Gonzales A, Nishimoto K, Tam WY, Soh D, Bilchik AJ, Katopodis N, Morton DL. Gangliosides as targets for immunotherapy of pancreatic adenocarcinoma. Cancer 2000;88:1828-1836.
55. Habal N, Gupta R, Bilchik AJ, Johnson T, Morton DL. TA90 – IC, a new marker for advanced colon cancer. Ann Surg Oncol 2000;7:352-356.
56. 56. Tsioulias GT, Wood TF, Morton DL, Bilchik AJ. Lymphatic mapping and focused analysis of sentinel lymph nodes upstage gastrointestinal neoplasms. Arch Surg 2000;135(8):926-932.
57. Wood TF, Rose DM, Allegra DP, Foshag LJ, Bilchik AJ. Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Ann Surg Oncol 2000;7(8): 593-600.
58. Ravindranath MH, Shen P, Habal N, Soh D, Nishimoto K, Gonzalez A, Tam WY, Bilchik AJ, Morton DL. Does human melanoma express carcinoembryonic antigen? Anticancer Res 2000;20(5A): 3083-3092.
59. Wood TF, Tsioulias GJ, Rangel D, Hutchinson W, Foshag LJ, Morton DL, Bilchik AJ. Focused examination of sentinel lymph nodes upstages early colorectal carcinoma. Am Surg 2000;66(11):998-1003.
60. Habal N, Sims C, Bilchik AJ. Gastrointestinal carcinoid tumors and second primary malignancies. J Surg Oncol 2000;75:306-310.
61. Bilchik AJ, Tsioulias GJ, Wood TF, Morton DL. Lymphatic mapping and sentinel lymphadenectomy: a novel technique to improve staging in patients with gastrointestinal neoplasms. In ASCO 2001 Education Book, edited by Perry MC. American Society for Clinical Oncology, Alexandria, VA, 2001, pp535-540.
62. Bilchik AJ, Wood TF, Chawla SP, Rose DM, Chung MH, Stern SS, Foshag LJ, Ramming KP. Systemic irinotecan or regional floxuridine chemotherapy prolongs survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-fluorouracil. Clin Colorectal Cancer 2001;1(1):36-42.
63. Bilchik AJ, Wood TF, Chung MH, Rose DM. Laparoscopic radiofrequency ablation of hepatic malignancies. In Surgical Laparoscopy, 2nd edition, edited by Zucker KA. Lippincott, Williams & Wilkins, 2001, pp 221-225.
64. Chung MH, Foshag LJ, Bilchik AJ. Management of incidental gallbladder carcinoma following laparoscopic cholecystectomy. Contemp Surg 2001;57:506-511.
65. Wood TF, Bilchik AJ. Radiofrequency thermal ablation as treatment for liver cancer at the John Wayne Cancer Institute. Oncology Issues 2001;16:17-20.
66. Bilchik AJ, Wood TF, Allegra DP. Radiofrequency ablation of unresectable hepatic malignancies: lessons learned. Oncologist 2001;6:24-33.
67. Bilchik AJ, Saha S, Stonecypher JA, Wood TF, Sostrin S, Turner RR, Wang H, Morton DL, Hoon DSB. Molecular staging of early colon cancer based on sentinel node analysis: A multicenter phase II trial. J Clin Oncol 2001;19:1128-1136.
68. Miyashiro I, Kuo C, Huynh K, Iida A, Morton DL, Bilchik AJ, Giuliano A, Hoon DSB. Molecular Strategy for Detecting Metastatic Cancers with Use of Multiple Tumor-specific MAGE-A Genes. Clin Chem 2001;47:505-512.
69. Wood TF, Saha S, Morton DL, Tsioulias GJ, Rangel D, Hutchinson W, Foshag LJ, Bilchik AJ. Validation of lymphatic mapping in colorectal cancer: in-vivo, ex-vivo, and laparoscopic techniques. Ann Surg Oncol 2001;8:150-157.
70. Ravindranath MH, Gonzales A, Soh D, Nishimoto K, Tam WY, Bilchik A, Morton DL, O’Day S. Interleukin-2 binds to ganglioside GD(1b). Biochem Biophys Res Commun 2001;283:369-373.
71. Chung MH, Ye W, Ramming KP, Bilchik AJ. Repeat hepatic cryotherapy for metastatic colorectal cancer. J Gastrointest Surg 2001;5:287-293.
72. Habal N, Gupta RK, Bilchik AJ, Yee R, Leopoldo Z, DDM, Ye W, Elashoff RM. Morton DL. CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer. Ann Surg Oncol 2001;8:389-401.
73. 73. Tsioulias GJ, Wood TF, Morton DL, Bilchik AJ. Diagnostic laparoscopy and laparoscopic ultrasonography optimize staging and resectability of intraabdominal tumors. Surg Endosc 2001;15:1016-1019.
74. Chung MH, Wood TF, Tsioulias GJ, Rose DM, Bilchik AJ. Laparoscopic radiofrequency ablation of unresectable hepatic malignancies: a phase II trial. Surg Endosc 2001;15:1020-1026.
75. Rose DM, Essner R, Hughes TM, Tang PC, Bilchik A, Wanek LA, Thompson JF, Morton DL. Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. Arch Surg 2001;136:950-955.
76. Wood TF, Spirt M, Rangel D, Shen P, Tsioulias GJ, Morton DL, Bilchik AJ. Lymphatic mapping improves staging during laparoscopic colectomy for cancer. Surg Endosc 2001;15:715-719.
77. 77. Bilchik AJ, Saha S, Tsioulias GJ, Wood TF, Morton DL. Aberrant drainage and missed micrometastases: the value of lymphatic mapping and focused analysis of sentinel lymph nodes in gastrointestinal neoplasms. Ann Surg Oncol 2001;8(9S):82S-85S.
78. Saha S, Bilchik A, Wiese D, Espinosa M, Badin J, Ganatra BK, Desai D, Kaushal S, Singh T, Arora M. Ultrastaging of colorectal cancer by sentinel lymph node mapping technique  a multicenter trial. Ann Surg Oncol 2001;8(9S):94S-98S.
79. Chung MH, Pisegna J, Spirt M, Giuliano AE, Ye W, Ramming KP, Bilchik AJ. Hepatic cytoreduction followed by a novel long-acting somatostatin analogue: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery 2001;130:954-962.
80. Yoon DY, Hines OJ, Bilchik AJ, Lewin K, Cortina G, Reber HA. Solid and papillary epithelial neoplasms of the pancreas: Aggressive resection for cure. Am Surg 2001;67:1195-1199.
81. Taback B, Nakayama T, Wiese D, Turner R, Bilchik AJ, Saha S, Hoon D. Detection of colorectal micrometastases in sentinel lymph nodes using the novel approach of PCR PNA clamping. Proc Am Assoc Cancer Res 2001;42:612.
82. Perez CA, Ravindranath MH, Gupta RK, Wood TF, van de Velde CJ, Tollenar RA, Soh D, Morton DL, Bilchik AJ. Serum total gangliosides and TA90-IC levels: novel immunologic markers in colorectal cancer. Cancer J, 2002;8:55-61.
83. Litvak DA, Wood TF, Tsioulias GJ, Chung M, Chawla SP, Foshag LJ, Morton DL, Ramming KP, Bilchik AJ. Systemic irinotecan and regional floxuridine following hepatic cytoreduction in 185 patients with unresectable colorectal cancer metastases. Ann Surg Onc 2002;9:148-155.
84. Saha S, Bilchik AJ, Wiese D. Sentinel lymph-node mapping in colorectal cancer. In Colorectal Cancer: A Clinical Guide to Therapy, edited by Bleiberg H, Kemeny N, Rougier P, Wilke H.
85. Chung MH, Gupta RK, Bilchik AJ, Ye W, Yee R, Morton DL. Preoperative serum TA90-IC as an adjunct to serum CA 19-9 in the diagnosis of pancreatic malignancy: a pilot study. Current Surg 2002;59:194-8.
86. Bilchik AJ, Nora D, Tollenaar RAEM, van de Velde CJH, Wood T, Turner R, Morton DL, Hoon DSB. Ultrastaging of early colon cancer using lymphatic mapping and molecular analysis. Eur J Ca 2002;38:977-85.
87. Wood TF, Nora DT, Morton DL, Turner RR, Rangel D, Hutchinson W, Bilchik AJ. One hundred consecutive cases of sentinel lymph node mapping in early colorectal carcinoma: Detection of missed micrometastases. J Gastrointest Surg 2002;6:322-30.
88. Bilchik AJ, Nora DT. Lymphatic mapping of nodal micrometastasis in colon cancer: Putting the cart before the horse? Ann Surg Onc 2002;9:529-31.
89. Tsioulias GJ, Wood TF, Spirt M, Morton DL, Bilchik AJ. A novel lymphatic mapping technique to improve localization and staging of early colon cancer during laparoscopic colectomy. Am Surg 2002;68:561-5.
90. Morton DL, Hsueh EC, Essner R, Foshag LJ, O’Day SJ, Bilchik A, Gupta RK, Hoon DS, Ravindranath M, Nizze JA, Gammon G, Wanek LA, Wang HJ, Elashoff RM. Prolonged survival of patients receiving active immunotherapy with canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Am Surg 2002;236:438-49.
91. Ravindranath MH, Wood TF, Soh D, Gonzales A, Muthugounder S, Perez C, Morton DL, Bilchik AJ. Cryosurgical ablation of liver tumors in colon cancer patients increases the serum total ganglioside level and then selectively augments antiganglioside IgM. Cryobiology 2002;45:10-21.
92. Bilchik AJ, Nora DT, Saha S, Turner RR, Wiese D, Kuo C, Ye X, Morton DL, Hoon DS. Molecular profiling of early colon cancer predicts micrometastases. Arch Surg 2002;137:1377-1383.
93. Bleicher RJ, Bilchik AJ. Radiofrequency ablation in 447 complex unresectable liver tumors: Lessons learned. Ann Surg Onc 2002;10:52-58.
94. Litvak DA, Bilchik AJ, Cabot MC. Modulators of ceramide metabolism sensitize colorectal cancer cells to chemotherapy: A novel treatment strategy. J Gastrointest Surg 2003;7:140-148.
95. 95. Bilchik AJ, Nora DT, Sobin LH, Turner RR, Trocha SD, Krasne D, Morton DL, Bilchik AJ. Effect of lymphatic mapping on the new Tumor-Node-Metastasis classification for colorectal cancer. J Clin Onc 2003;21:668-672.
96. Trocha S, Nora DT, Saha SS, Morton DL, Trocha SD, Wiese D, Bilchik AJ. Combination probe and dye-directed lymphatic mapping detects micrometastases in early colorectal cancer. J Gastrointest Surg 2003;7:340-346.
97. Bilchik AJ. More (nodes) + more (analysis) = less (mortality): Challenging the therapeutic equation for early-stage colon cancer. Ann Surg Oncol 2003; 10:203-205.
98. Takeuchi H, Bilchik A, Saha S, Turner R, Wiese D, Tanaka M, Kuo C, Wang H, Hoon DSB. Quantitative c-MET mRNA expression in primary colon cancer: A predictor of tumor invasion and lymph node metastases. Clin Cancer Res 2003;9:1480-1488.
99. Bilchik AJ. Arterial chemotherapy as adjuvant and palliative treatment of hepatic colorectal metastases: An update. Surg Onc Clin North Amer 2003;12:193-210.
100. Yao K, Bilchik A. Local excision of a small squamous cell carcinoma of the anal canal: Case report and review of the literature. Contemp Surg, 2003;59:126-131.
101. Curley SA, Bilchik AJ, Fraker DL, McMasters KM. Symposium: Radiofrequency ablation of hepatic malignancies. Contemp Surg, 2003;59:162-172.
102. Litvak D, Bleicher RJ, Bilchik AJ. RFA of a refractory unresectable insulinoma of the pancreas. Contemp Surg 2003;59:229-232.
103. Turner RR, Nora DT, Trocha SD, Bilchik AJ. Colorectal carcinoma nodal staging. Frequency and nature of cytokeratin-positive cells in sentinel and non-sentinel lymph nodes. Arch Path Lab Med 2003;127:673-679.
104. Bleicher RJ, Bilchik AJ. Complications of hepatic RFA: Lessons learned. In Radiofrequency Ablation of Cancer: Current Indications, Techniques, and Outcomes, edited by Ellis LM, Curley SA, Tanabe KK. Springer-Verlag, New York, 2003, pp 121-134.
105. Bilchik AJ. Thermal ablation of hepatic colorectal metastasis: should this minimally invasive technique replace resection? In ASCO 2003 Education Book, edited by Perry MC. American Society for Clinical Oncology, Alexandria, VA, 2003, pp 699-710.
106. Morton DL., Hoon DS, Cochran AJ, Turner RR, Essner R, Takeuchi H, Wanek LA, Glass E, Foshag LJ, Hsueh EC, Bilchik AJ, Elashoff D, Elashoff R. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: Therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg 2003;238:538-550.
107. Bilchik AJ, Trocha SD. Lymphatic mapping and sentinel node analysis to optimize laparoscopic resection and staging of colorectal cancer: An update. Cancer Control 2003;10:219-223.
108. Trocha SD, Saha SS, Wiese D, Thompson J, Morton DL, Bilchik AJ. Differential expression of thymidylate synthase in colorectal tumors and matched lymph nodes: Impact on adjuvant treatment. Am Surg 2003;69:918-922.
109. Bilchik AJ, Faries M. Radiofrequency ablation of hepatic malignancies: Inexpensive and minimally invasive, but should it replace resection? Ann Surg Oncol 2003;10:1002-1004.
110. Bilchik AJ, Essner R, Thompson JF, Morton DL. Hepatic surgery for metastatic melanoma. In Textbook of Melanoma: Pathology, Diagnosis and Management, edited by Thompson JF, Morton DL, Kroon BBR. Martin Dunitz Publishers, London, 2004, pp 505-513.
111. Taback B, Bilchik AJ, Saha S, Nakayama T, Wiese DA, Turner RR, Kuo CT, Hoon DSB. Peptide nucleic acid clamp PCR: A novel K-ras mutation detection assay for colorectal cancer micrometastases in lymph nodes. Int J Cancer 2004; 111: 409-414.
112. Bilchik AJ, Martinez S. Novel effective drugs and evolving ablation technology: A more comprehensive approach to hepatic malignancies. Ann Surg Oncol 2004; 11: 458-459.
113. Saha S, Dan AG, Bilchik AJ, Kitagawa Y, Schochet E, Choudri S, Saha L, Wiese D, Morton D, Kitajima M. Historical review of lymphatic mapping in gastrointestinal malignancies. Ann Surg Oncol 2004; 11: 245S-249S.
114. Umetani N, Fujimoto A, Takeuchi H, Shinozaki M, Bilchik AJ, Hoon DS. Allelic imbalance of APAF-1 locus at 12q23 is related to progression of colon carcinoma. Oncogene 2004; 23(50): 8292-300.
115. cancer (T1 & T2) by sentinel lymph node (SLN) mapping. Ann Surg Oncol 2004;11(2):S109-S110.
116. Umetani N, Takeuchi H, Fujimoto A, Shinozaki M, Bilchik AJ, Hoon DS. Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis. Clin Cancer Res 2004; 10:7475-7483.
117. Martinez SR, Bilchik AJ. Quality control issues in the management of colon cancer patients. Eur J Surg Onc, 2005; 31: 616-629.
118. Martinez S, Bilchik AJ. Lymphatic mapping and sentinel node analysis in colon cancer: A review. Clinical Colorectal Cancer, 2005; 4: 320-324.
119. Kim J, Takeuchi H, Lam ST, Turner RR, Wang H-J, Kuo C, Foshag L, Bilchik AJ, Hoon DSB. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 2005; 23:2744-2753.
120. Takeuchi H, Kim J, Fujimoto A, Umetani N, Mori T, Bilchik AJ, Turner R, Tran A, Kuo C, Hoon DS. X-linked inhibitor of apoptosis protein expression level in colorectal cancer is regulated by hepatocyte growth factor/C-Met pathway via AKt signaling. Clin Cancer Res 2005; 11:7621-7628.
121. 121. Bilchik AJ, Poston G, Curley SA. Strasberg S, Saltz L, Adam R, Nordlinger B, Rosen LS, Rougier P. Neoadjuvant
122. Martinez SR, Young SE, Giuliano AE, Bilchik AJ. The utility of estrogen receptor, progesterone receptor and HER-2/neu status to predict survival in patients undergoing resection for breast cancer metastases. Am J Surg 2006; 191:281-283.
123. Saha S, Seghal R, Patel M, Doan K, Dan A, Bilchik A, Beutler T, Wiese D, Bassily N, Yee C. A multicenter trial of sentinel lymph node mapping in colorectal cancer:prognostic implications for nodal staging and recurrence. Am J Surg 2006; 19:305-310
124. Kim J, Mori T, Chen SL, Amersi FF, Martinez SR, Kuo C, Turner RR, Ye X, Bilchik AJ, Morton DL, Hoon DSB. Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg 2006;244:113-120
125. Chen, SL, Iddings DM, Schrei RP, Bilchik AJ. Lymphatic mapping and sentinel node analysis: current concepts and applications. CA Cancer J Clin 2006;56:292-309
126. Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving respectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006;13:1271-80
127. 127. Zogakis TG, Bilchik AJ. Radiofrequency thermal ablation of liver tumors. In Textbook Surgery of the Liver, Biliary Tract and Pancreas, 4th Edition, edited by Blumgart LS, Belghiti J. Elsevier, Philadelphia, PA, October 2006
128. Kim J, Takuji M, Amersi F, Martinez S, Kuo C, Turner RR, Yi C, Bilchik AJ, Morton DL, Hoon DSB. Chemokine receptor CXCR4 expression by melanoma and colorectal cancer facilitates liver metastasis and correlates with disease outcome. Ann Surg Oncol, 2006; 244(1) 113-120.
129. Martinez SR, Young SE, Hoedema R, Foshag LJ, Bilchik AJ. Colorectal cancer screening and surveillance: Current standards and future trends. Ann Surg Oncol 2006; 13(6):768-775.
130. Kim J, Reber HA, Hines OJ, Kazanjian KK, Tran A, Ye X, Amersi FF, Martinez SR, Dry SM, Bilchik AJ, Hoon DSB. The clinical significance of MAGE-3 expression in pancreatic cancer. Int J Cancer, 2006; 118(9) 2269-2275.
131. Bilchik AJ. Novel Insights into the Diagnosis and Treatment of Melanoma. In Melanoma- Surgical Oncology Clinics of North America, edited by Petrelli N, Bilchik AJ, Elsevier, Philadelphia, PA, 2006; 240pgs
132. Amersi FF, McElrath-Garza A, Ahmad A, Zogakis T, Allegra DP, Krasne R, Bilchik AJ. Long Term Survival after Radiofrequency Ablation of Complex Unresectable Liver Tumors. Arch Surg, 2006;141(6):581-588
133. Bilchik AJ, DiNome M, Saha S, Turner R, Wiese D, McCarter M, Hoon DSB, Morton DL. Prospective multicenter trial of staging adequacy in colon cancer: preliminary results. Arch Surg, 2006;141(6):527-534
134. Martinez S, Chen S, Bilchik AJ. Treatment disparities in Hispanic rectal cancer patients: a SEER database study. Am J Surg 2006;72:906-908
135. Aikou T, Kitagawa Y, Kitajima M, Uenosono Y, Martinez SR, Bilchik AJ, Saha S. Sentinel Lymph Node Mapping for GI Cancer. Cancer Metastasis Reviews (supplemental issue), 2006; 25(2):269-277.
136. Umetani N, Kim J, Hiramatsu S, Bilchik AJ, Reber HA, Hines OJ, Hoon DS. Elevated integrity of free circulating DNA in sera of colorectal and periampullary cancer patients: A direct quantitative PCR for ALU repeats. Clin Chem, 2006;52(6) 1062-1069.
137. Kim J, Reber HA, Dry SM, Elashoff D, Chen S, Umetani N, Kitago M, Hines OJ, Kazanjian KK, Hiramatsu S, Bilchik AJ, Yong S, Shoup M, Hoon D. Unfavorable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins. Gut, May 2006;55:1598-1605.
138. Iddings DM, Ahmad A, Elashoff D, Bilchik AJ. The Prognostic Effect of Micrometastases in Previously Staged Lymph Node Negative (N0) Colorectal Carcinoma: A Meta-analysis. Ann Surg Oncol, 2006;13:1386-1392
139. Chen SL, Bilchik AJ. More extensive nodal dissection improves survival for stages I to III of colon cancer: a population-based study. Ann Surg 2006;244:602-610
140. Ahmad A, Chen SL, Kavanagh MA, Allegra DP, Bilchik AJ. Radiofrequency ablation of hepatic metastases from colorectal cancer: are newer generation probes better? Am Surg. 2006;72(10):875-9
141. Bilchik AJ. Colorectal cancer metastatic to the liver: radiofrequency ablation. In Current Surgical Therapy, edited by Cameron JL. Ninth edition. Elsevier, Philadelphia, 2007
142. Bilchik AJ. Current and emerging trends in the treatment of early-stage colorectal cancer: importance of a multidisciplinary approach. Hematol Oncol Clin, North Am 2007;21(Suppl 1):8-18
143. Bilchk, AJ. Summary on “More extensive nodal dissection improves survival for stages I to III of colon cancer: a population-based study”. NEJM, 2007
144. Kavanagh MA, Ahmad A, Amadpour M, Bilchik AJ. Image of the month: serrated adenomatous polyposis. Arch Surg 2007; 142(9):902
145. Nicholl MB, Bilchik AJ. Radiofrequency ablation of colorectal carcinoma liver metastases Current Colorectal Cancer Reports. Volume 3: Issue 2, April 2007;3: 99-103
146. Iddings DM, Koda EA, Gewel SS, Parker R, Saha D, Bilchik AJ. Angiogenesis markers in early colorectal cancer predict lymph node metastases. Arch Surg, 2007; 142:738-745
147. Chen SL, Bilchik AJ. Resecting lymph nodes in colon cancer: more than a staging operation? Ann Surg Oncol 2007; 14:2175-2176
148. Iddings DM, Bilchik AJ. Gastric Carcinoma: Applying the sentinel node paradigm to improve the Understanding of metastatic patterns and the possible role of selective lymphadenectomy. Ann Surg Oncol 2007; 14:2432-2434
149. Bilchik, AJ, Compton C. Close collaboration between surgeon and pathologist is essential for accurate Staging of early colon cancer. Ann Surg, 2007;245:864
150. Ahmad A, Chen SL, Bilchik, AJ. Role of repeated hepatectomy in the multimodal treatment of Hepatic colorectal metastases. Arch Surg 142:526-531, 2007
151. Wright BE, Lee C, Bilchik AJ. Hepatic cytoreductive surgery for neuroendocrine cancer. Surg Oncol Clin N Am, 2007;16:627-637
152. 152. Iddings D, Bilchik AJ. The biologic significance of micrometastatic disease and sentinel lymph node technology on colorectal cancer. Seminars in Surgical Oncology. J Surg Oncol, 2007:96(8);671-678
153. Wright BE, Bilchik AJ. Management of T2 Gallbaladder Cancer: Are practice patterns consistent with national recommendations? Am J Surg Dec 2007; 194(6):820-826
154. Bilchik AJ, Hoon DSB, Saha S, Weise D, DiNome M, Turner R, Koyanga K, McCarter M, Shen P, Iddings D, Chen SL, Gonzales M, Elashoff D, Morton DL. Prognostic Impact of Micrometastases In Colon Cancer: Interim Results of A Prospective Multicenter Trial. Annals of Surg 2007;246(4):568-577
155. Rosen L, Bilchik AJ, Beart RW, Benson AB, Chang KJ, Compton CC, Grothey A, Haller DH, Ko CY, Lynch PM, Nelson H, Stamos M, Turner R, Willett CG. New Approaches to Assessing and Treating Early-Stage Colon and Rectal Cancer. Clin Cancer Research 2007;13:6853-6
156. de Maat MF, Van de Velde C, Umetani N, de Heer P, Putter H, Van Hoesel A, Meijer GA, Van Grieken NC, Kuppen PJ, Bilchik AJ, Tollenaar R, Hoon DS. Epigenetic Silencing of Cyclooxygenase-2 Affects Clinical Outcome in Gastric Cancer. J Clin Oncol 2007; 25:4887-4894
157. Bilchik AJ. Current and Emerging Strategies for the Treatment of Unresectable Hepatic Neuroendocrine Metastases. A century of Advance in Neuroendocrine Tumor Disease, 2008; 427-433
158. Nicholl M, Bilchik AJ. Is routine use of sentinel node biopsy justified in colon cancer (commentary)? Ann Surg Oncol, 2008:15(1);1-3
159. Iddings DM, Wright BE, Bilchik AJ. A rare cause of primary hepatic neoplasm: malignant peripheral nerve sheath tumor (MPNST) in the age of modern liver surgery. Am Surg, 2008; 74:47-50
160. Nicholl, M, Bilchik AJ. Thermal Ablation of Hepatic Malignancy: Useful But Still Not Optimal. Eur J Surg Oncol, 2008; 34:318-23
161. Koyanagi K, Bilchik AJ, Saha S, Turner RR, et al. Clinical relevance of occult nodal micrometastases and circulating tumor cells in early colorectal cancer in a prospective multicenter trial. Clin Cancer Research 2008; 22:7391-7396
162. deMaat M, van de Velde C, van der Werff M, Putter H, Umetani N, Klein-Kranenbarg E, Turner R, van Krieken J, Bilchik AJ, Tollenaar R, Hoon D. Quantitative Analysis of Methylation of Genomic Loci in Early Stage Rectal Cancer Predicts distant Recurrence. J Clin Oncol 2008; 26:2327-35
163. Bilchik AJ, Hecht JR. Perioperative Risks of Bevacizumab and other Biological Agents for Hepatectomy: Theoretical or Evidence Based? J Clin Oncol 2008; 26:1786-9
164. Wasif N, Sasu S, Conway W, Bilchik AJ. Focal Nodular Hyperplasia (FNH): Report of an Unusual Case and Review of the Literature. Am Surg 2008; 74:1100-1103
165. Graeme J Poston, Joan Figueras, Felice Giuliante ,Gennaro Nuzzo, Alberto F Sobrero, Jean-Francois Gigot, Bernard Nordlinger, Rene Adam, Thomas Gruenberger, Michael A Choti, Anton J Bilchik, Eric Van Cutsem, Michael I D’Angelica. Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol 2008; 29:4828-4833
166. Telian SH, Bilchik AJ. Significance of the Lymph Node Ratio in Stage III Colon Cancer. Ann Surg Oncol 2008; 6:1557-1558
167. Stojadinovich A, Nissan A, Protic M, Bilchik AJ, Peoples G. Targeted Nodal Assessment in Colon Cancer. Ann Surg 2008; 5:902-904
168. Bilchik AJ, Poston G, Adam R, Choti M. Prognostic Variables for Colorectal Cancer Hepatic Metastases: An Evolving Paradigm! J Clin Oncol 2008; 26:5320-5321
169. Nicholl M, Bilchik AJ. Is routine use of sentinel node biopsy justified in colon cancer? Ann Surg Oncol 2008; 1:1-3
170. Bilchik AJ, Stojadinovic A, Wainberg Z, Hecht JR. Targeted lymph node evaluation in colorectal cancer: a decade of progress! J Surg Oncol 2009 5:273-274
171. Cahill RA, Bembenek A, Sirop S, Waterhouse DF, Schneider W, Leroy J, Wiese D, Beutler T, Bilchik AJ, Saha, S, Schlag PM. Sentinel node biopsy for individualization of surgical strategy for cure of early-stage colon cancer, Ann Surg Oncol 2009:16;2170-80.
172. Nissan, A, Protic P, Bilchik AJ, Eberhardt J, Peoples GE, Stojadinovic, A. Predictive Model of Outcome of Targeted Nodal Assessment in Colorectal Cancer. Annals of Surgery 2010:251;265-74.
173. Bilchik AJ. Ablation of Hepatic Malignancies: From Radiofrequency to Microwave – A New Generation of Technology. Journal of Interventional Oncology 2009:2;121-127.
174. Wasif N, Faries MB, Saha S, Turner RR, Wiese D, McCarter M, Shen P, Stojadinovic A, Bilchik AJ. Primary colorectal tumor characteristics as predictors of occult nodal metastasis in a prospective multicenter trial Surgery, 2010:147;352-7.
175. Bilchik AJ, Nissan A, Wainberg Z, Shen P. Surgical Quality and Nodal Ultra-staging is Associated with Long-term Disease-free Survival in Early Colorectal Cancer: An Analysis of Two International Multi-center Prospective Trials. Annals of Surgery, 2010:252;467-74
176. Bilchik AJ, Gonzalez M, Stojadinovic, A. The Applications of Sentinel Lymph Node to Cancer. In Press Advances in Minimally Invasive Surgery. Ed Fred Greene
177. Nicholl MB, Conway W, Ye X, Bilchik AJ, Singh G. Should Microwave Energy Be Preferred to Radiofrequency Energy for Malignant Liver Tumor Ablation? J Interventional Oncology 2010:3(1); 201-210.
178. Bilchik, AJ, Stojadinovic A. Is it time to move beyond lymph node evaluation in staging colon cancer? Arch Surg. 2010 Sep;145(9):830-1.
179. Steele SR, Chen SL, Stojadinovic A, Nissan A, Zhu K, Peoples GE, Bilchik AJ. The impact of age on quality measure adherence in colon cancer. J Am Coll Surg. 2011 May 19. [Epub ahead of print]
180. Soni M, Wiese D, Korant A, Sirop S, Chakravarty B, Gayar A, Bilchik AJ, Beutler T, Ratz D, Saha S. .Comparison of nodal positivity between SLNM vs conventional surgery in colon cancer patients with <12 and ≥12 lymph nodes harvested. Am J Surg. 2011 Jan 29. [Epub ahead of print]
181. Chen SL, Steele SR, Eberhardt J, Zhu K, Bilchik AJ, Stojadinovic A. Lymph node ratio as a quality and prognostic indicator in stage III colon cancer. Ann Surg. 2011 Jan;253(1):82-7.
182. Garreau, J, Wasif, N., Yao, K., Bilchik, AJ. Treatment Patterns for Micrometastases of Colon Cancer. Submitted American J Surgery 2011

1. Adrian T, Zucker KA, Bilchik AJ, Modlin IM. Cholecystokin receptor antagonist blocks diet-induced pancreatic hypertrophy in the hamster. Clin Res 1987;35(5):796A.
2. Bilchik AJ, Zucker KA, Adrian TE, Modlin IM. Amelioration of traumatic pancreatitis by a new specific CCK receptor antagonist. Gastroenterology 1988;94:A35.
3. Adrian TE, Bilchik AJ, Zucker KA, Modlin IM. Cholecystokinin receptor antagonist blocks fat induced pancreatic growth but increases food intake and body weight in the hamster. Gastroenterology 1988;94:A3.
4. Longo WE, Ballantyne GH, Vukasin AP, Bilchik AJ, Adrian TE, Modlin IM. Bile salts release peptide tyrosine tyrosine. Gastroenterology 1988;94:A269.
5. Bilchik AJ, Fielding LP, Basson MD, Zucker KA, Ballantyne GH, Adrian TE, Modlin IM. Postpransial portosystemic differences in secretion and somatostatin release in the dog. Gastroenterology 1988;94:A34.
6. Zucker KA, Adrian TE, Bilchik AJ, Modlin IM. Is cholecystokinin responsible for normal pancreatic growth? Gastoenterology 1988;94:A518.
7. Adrian TE, Bilchik AJ, Zucker KA, Modlin IM. CCK receptor blockade increases hamster body weight and food intake. FASEB Journal 1988;2(4):A737.
8. Bilchik AJ, Zucker KA, Sussman J, Adrian TE, Modlin IM. New specific CCK receptor antagonist ameliorates surgically induced pancreatitis both pre and post insult. Br J Surg 1988.
9. Bilchik AJ, Nilsson O, Modlin IM, Zucker KA and Adian TE. Rapid carcinoid tumor induction in mastomys with H2 receptor blockade. Connecticut Med 1988.
10. Armstrong DN, Bilchik AJ, Adrian TE, Zucker KA, Modlin IM. PYY and enteroglucagon levels are elevated after proctocolectomy and pelvic ileal-anal anastomosis. Gastroenterology 1989;96:A15.
11. Bilchik AJ, Zucker KA, Adrian TE, Modlin IM. Parenteral, but not oral L369,718 ameliorates acute experimental pancreatitis. Gastroenterology 1989;96;A45.
12. Zucker KA, Bilchik AJ, Leach SD, Adrian TE, Modlin IM. Continuous cholecystokinin receptor blockade in newborn guinea pigs: impaired growth and altered secretagogue response. Gastroenterology 1989;96;A568.
13. Nillson O, Bilchik AJ, Adrian TE, Modlin IM. Gastric carcinoids of praomys natalensis contain PYY and enteroglucagon like immunoreactivity. Gastroenterology 1989;96;A366.
14. Savoca PE, Ballantyne GH, Adrian TE, Bilchik AJ, Pernikoff B, Modlin IM. Xylocaine does not inhibit deoxycholate stimulated PYY release. Gastroenterology 1989;96;A444.
15. Vukasin AP, Ballantyne GH, Adrian TE, Bilchik AJ, Pernikoff B, Modlin IM. Elevations in plasma and tissue PYY after colectomy. Gastroenterology 1989;96.
16. Modlin IM, Bilchik AJ, Kacinski B, Esterline W, Goldenring JR. Oncogene amplification in gastric carcinoid tumors induced by acid secretory blockade in mastomys. Gastroenterology 1990.
17. Bilchik AJ, Hines OJ, Zinner MJ, Adrian TE, McFadden DW, Ashley SW. Physiological significance of PPY in small intestinal absorption in vivo. Gastroenterology 1993;623:A157.
18. Bilchik AJ, Hines OJ, Zinner MJ, Berger JJ, McFadden DW, Adiran TE, Ashley SW. PYY augments postprandial small intestinal absorption in vivo. Gastroenterology 1993;506:A127.
19. Hines OJ, Bilchik AJ, Rodgers PJ, Berger J, Zinner MJ, Ashley SW. Na+/H+ exchange regulates postprandial ileal absorption. Gastroenterology 1993;611:A153.
20. Kelley MC, Bostick P, Bilchik AJ, Foshag LJ, Essner R, Kuo C, Conrad A, Boasberg PD, Hoon DSB. Molecular detection of pancreatic carcinoma (PC) with a multiple marker RT-PCR assay. Proc Am Soc Clin Oncol 1997;16:293a.
21. Sarantou T, Bilchik AJ, Ramming K. Cryoablation of primary and metastatic liver cancer unresponsive to conventional therapy. Proc Am Soc Clin Oncol 1997;16:304a.
22. Bilchik AJ, Ravindranath MH, Chu KU, Soh D, Morton DL. Polyvalent vaccine includes an immune response to carbohydrate antigens in stage IV colon cancer. Proc Am Soc Clin Onc 1999;18:455a.
23. Bilchik AJ, Chawla S, Rose DM, Stern S, Ramming KP. Systemic irinotecan (CPT-11) and regional chemotherapy prolong survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-fluorouracil (5-FU). . Proc Am Soc Clin Onc 1999;18:254a.
24. Chu KU, Ravindranath MH, Nishimoto K, Bilchik AJ, Morton DL. Cell-surface expression of an immunogenic ganglioside (GM2) in pancreatic adenocarcinoma. Proc Am Assoc Cancer Res 1999;40:470a.
25. Ravindranath MH, Bilchik AJ, Chu K, Soh D, Shen P, Morton DL. Anti-GM2 IgM inversely correlates with the serum ganglioside level in colon cancer patients after vaccine therapy. Proc Am Assoc Cancer Res 1999;40:577a.
26. Bilchik AJ, Saha S, Stonecypher JA, Wood TF, Hoon DS. Molecular staging of early colon cancer: lymphatic mapping and sentinel node analysis for occult micrometastasis. Proc Am Soc Clin Oncol 2000;19:248a.
27. Saha S, Bilchik AJ, Wiese D, Nora D, Badin J, Espinosa M, Ganatra BK, Seoane S, Gomez E, Singh T, Arora M. Phase II study for upstaging of colorectal cancer (CRCA) by sentinel lymph node mapping (SLNM) technique - a multicenter trial. Proc Am Soc Clin Oncol 2000;19:239a.
28. Bilchik AJ, Ravindranath M, Gupta R, Habal N, Wood TF, Tsioulias GJ, Morton DL. CancerVax, a polyvalent vaccine improves survival in refractory stage IV colon cancer: a phase II trial. Proc Am Soc Clin Oncol 2001;20:252a.
29. Ravindranath MH, Wood TF, Soh D, Perez C, Gonzales AM, Morton DL, Bilchik AJ. Necrosis induced by cryotherapy of liver metastases increases serum ganglioside levels and provides an intrinsic adjuvant to augment specific IgM to tumor-associated gangliosides. Proc Am Assoc Cancer Res 2001;42:507a.
30. Saha S, Bilchik A, Espinosa M, Monson K, Nadimpalli R, Wiese D, Ganatra K, Desai D, Kaushal S, Nagaraju M. Results of a multi-institutional trial of sentinel lymph node mapping (SLNM) in colorectal cancer (CRCa). Proc Am Soc Clin Oncol 2001;584.
31. Taback B, Nakayama T, Wiese D, Turner R, Bilchik A, Saha S, Hoon D. Detection of colorectal micrometastasis in sentinel lymph nodes using the novel approach of PCR PNA clamping. Proc Am Assoc Cancer Res 2001;42:612a.
32. 32. Bilchik AJ, Perez CA, Tollenar W, Morton DL, van de Velde CJ. Multivariate analysis of 18 prognostic factors in early colon cancer: a prospective, multi-center trial. Proc Am Soc Clin Oncol 2002;21:172a.
33. Nora DT, Kadison AS, Trocha S, Riley C, Bilchik AJ, Morton DL. Does nodal micrometastasis alter the staging and management of early stage colorectal cancer? Proc Am Soc Clin Oncol 2002;21:117b.
34. Takeunchi H, Bilchik A, Saha S, Wiese D, Kuo C, Ye X, Hoon DSB. C-Met gene expression in primary colorectal cancer correlates with depth of tumor invasion and metastatic potential. Proc Am Assoc Cancer Res 2002;43:217.
35. Litvak, DA, Bilchik AJ, Cabot MC. Modulators of ceramide metabolism enhance irinotecan-mediated apoptosis of colon cancer cells by a p53-independent process. Ann Surg Oncol 2002;9(1):S10-S11
36. Bleicher RJ, Allegra DP, Nora DT, Wood TF, Foshag LJ, Bilchik AJ. Radiofrequency ablation in 406 complex unresectable liver tumors: Lessons learned. Ann Surg Oncol 2002;9(1):S8.
37. Yao K, Nora D, Ye X, Morton D, Bilchik A. Micrometastases in colon cancer: Perception versus reality. Ann Surg Oncol 2003;10(1):S62.
38. Kim J, Takeuchi H, Foshag L, Bilchik A, Hoon DSB. Colorectal cancer expression of chemokine receptor CXCR4 promotes liver metastasis. Proc Am Soc Clin Oncol 2004; 23:266.
39. Kim J, Mori T, Lam S, Nguyen L, Morton D, Bilchik AJ, Hoon DSB. CXCR4 chemokine receptor mediates melanoma and colorectal cancer metastasis to the liver. J Am Coll Surg 2004; 199(3S):81.
40. Umetani N, Shinozaki M, Fujimoto A, Takeuchi H, Bilchik AJ, Hoon DS. Allelic loss at the APAF-1 locus facilitates colorectal carcinogenesis and metastasis to the liver. Proc Am Assoc Cancer Res 2004;45:764-765.
41. Saha S, Dan AG, Bilchik AJ, Beutler T, Doan K, AlSamkari R, Wiese D, Turner R, Barber K. Mechanisms of failure and skip metastasis in sentinel lymph node mapping for colorectal cancer. Ann Surg Oncol 2005;12(2):S83.
42. Martinez SR, Kuo CT, Bilchik AJ, Kim J, Morton DL, Hoon DSB. Downregulation of tumor suppressor Runx genes in malignant cutaneous melanoma. J Clin Oncol 2005; 23:717S.

Presented The Neuroimmunomodulatory role of cholecystokinin.

Presented Local Treatment of liver metastases

Presente A 5-year institutional experience with hepatic cryosurgery for unresectable colorectal metastases refractory to chemotherapy.

Presented  An alternative strategy in the treatment of patients with unresectable hepatomas.

Senior Author - Presentation Preoperative serum TA90-IC as an adjunct to serum CA 19-9 in the diagnosis of pancreatic malignancy: a pilot study.

Presented Prognostic factors and the role of chemotherapy in 153 patients undergoing cryosurgery for unresectable colorectal metastasis. 

Presented H2 receptor blockade induction peptide YY (PYY) and enteroglucagon (EG) secreting gastric carcinoids in mastomys. 

Presented Peptide YY immunoneutralizaton inhibits meal induced absorption in vivo.

Presented Cryosurgical palliation of metastatic neuroendocrine tumors resistant to conventional therapy.

Senior Author - Presentation Hepatic cytoreduction followed by a novel long-acting somatostatin analogue: a paradigm for intractable neuroendocrine tumors metastatic to the liver.

Presented Universal application of the sentinel node technique in solid cancers.

Presented Detection of pancreatic carcinoma with a novel multi-marker RT-PCR assay.

Presented Gangliosides as potential immunotherapy targets in pancreatic cancer.

Invited Lecturer Evolving techniques for treatment of metastatic tumors.

Invited Discussant Treatment of Pancreatic Pseudocyst of Percutaneous Endoscopic Cystogastrostomy.